Biodegradable mucoadhesive particulates for nasal and pulmonary antigen and DNA delivery
- PMID: 15560949
- DOI: 10.1016/j.addr.2004.09.004
Biodegradable mucoadhesive particulates for nasal and pulmonary antigen and DNA delivery
Abstract
Biodegradable polymer and particulate carriers have been shown to be of considerable potential for the delivery of peptides, proteins and DNA in animal models. In the context of vaccine delivery to the upper and lower respiratory tracts, the use of mucoadhesive agents offers a strategy for the facilitation of increased residence time and increased vaccine efficacy. Additional concerns addressed here include the potential of uptake of vaccine formulations by the primary olfactory nerves in the nasal cavity, effective delivery to the lung, strategies to maximise the immunopotentiation of candidate vaccine formulations, as well as the evaluation of animal models and interpretation of engendered immune responses in terms of antigen-specific antibody production. Experimental data are presented that demonstrate the potential of muco- and bioadhesive agents in combination with liposomes for intranasal (i.n.) delivery of tetanus toxoid in mice. A delivery system utilising chitosan for the formulation of microspheres by the spray-drying method is described and assessed for intranasal vaccine delivery, and porous particles with potential for pulmonary administration are also outlined.
Similar articles
-
Mono-N-carboxymethyl chitosan (MCC) and N-trimethyl chitosan (TMC) nanoparticles for non-invasive vaccine delivery.Int J Pharm. 2008 Nov 3;363(1-2):139-48. doi: 10.1016/j.ijpharm.2008.06.029. Epub 2008 Jul 9. Int J Pharm. 2008. PMID: 18662762
-
Nasal vaccine innovation.J Drug Target. 2010 Dec;18(10):771-86. doi: 10.3109/1061186X.2010.523790. J Drug Target. 2010. PMID: 21047271 Review.
-
The application of mucoadhesive polymers in nasal drug delivery.Drug Dev Ind Pharm. 2010 Mar;36(3):323-36. doi: 10.1080/03639040903170750. Drug Dev Ind Pharm. 2010. PMID: 19735210 Review.
-
Liposomes as delivery systems for nasal vaccination: strategies and outcomes.Expert Opin Drug Deliv. 2010 Jul;7(7):829-44. doi: 10.1517/17425247.2010.488687. Expert Opin Drug Deliv. 2010. PMID: 20459361 Review.
-
Nasal delivery of vaccines.J Drug Target. 1996;3(6):455-67. doi: 10.3109/10611869609015965. J Drug Target. 1996. PMID: 8863138 Review.
Cited by
-
Nanoparticles that do not adhere to mucus provide uniform and long-lasting drug delivery to airways following inhalation.Sci Adv. 2017 Apr 5;3(4):e1601556. doi: 10.1126/sciadv.1601556. eCollection 2017 Apr. Sci Adv. 2017. PMID: 28435870 Free PMC article.
-
Release and permeation profiles of spray-dried chitosan microparticles containing caffeic acid.Saudi Pharm J. 2018 Mar;26(3):410-415. doi: 10.1016/j.jsps.2017.12.021. Epub 2018 Jan 8. Saudi Pharm J. 2018. PMID: 29556132 Free PMC article.
-
Programmed Application of Transforming Growth Factor β3 and Rac1 Inhibitor NSC23766 Committed Hyaline Cartilage Differentiation of Adipose-Derived Stem Cells for Osteochondral Defect Repair.Stem Cells Transl Med. 2014 Oct;3(10):1242-51. doi: 10.5966/sctm.2014-0042. Epub 2014 Aug 25. Stem Cells Transl Med. 2014. PMID: 25154784 Free PMC article.
-
Strategies for intranasal delivery of vaccines.Drug Deliv Transl Res. 2013 Feb;3(1):100-9. doi: 10.1007/s13346-012-0085-z. Epub 2012 Jul 12. Drug Deliv Transl Res. 2013. PMID: 23316448 Free PMC article.
-
Chitosan nanoparticles as antigen vehicles to induce effective tumor specific T cell responses.PLoS One. 2020 Sep 30;15(9):e0239369. doi: 10.1371/journal.pone.0239369. eCollection 2020. PLoS One. 2020. PMID: 32997691 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical